Abstract
Despite long-term research achievements, the development of cell therapy (CT) products remains challenging. This is because the risks experienced by the subject and therapeutic effects in the clinical trial stage are unclear due to the various uncertainties of CT when administered to humans. Nevertheless, as autologous cell products for systemic administration have recently been approved for marketing, CT product development is accelerating, particularly in the field of unmet medical needs. The human experience of CT remains insufficient compared with other classes of pharmaceuticals, while there are countless products for clinical development. Therefore, for many sponsors, understanding the rationale of human application of an investigational product based on the consensus and improving the ability to apply it appropriately for CT are necessary. Thus, defining the level of evidence for safety and efficacy fundamentally required for initiating the clinical development and preparing it using a reliable method for CT. Furthermore, the expertise should be strengthened in the design of the first-in-human trial, such as the starting dose and dose-escalation plan, based on a sufficiently acceptable rationale.
| Original language | English |
|---|---|
| Pages (from-to) | 16-26 |
| Number of pages | 11 |
| Journal | International Journal of Stem Cells |
| Volume | 16 |
| Issue number | 1 |
| DOIs | |
| State | Published - 2023 |
Bibliographical note
Publisher Copyright:© 2023 by the Korean Society for Stem Cell Research
Keywords
- Cell and tissue-based therapy
- Drug approval
- Drug development
- Stem cells
Fingerprint
Dive into the research topics of 'Establishing Rationale for the Clinical Development of Cell Therapy Products: Consensus between Risk and Benefit'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver